PRO 1160
Alternative Names: GEN-1160; PRO-1160Latest Information Update: 27 May 2024
At a glance
- Originator ProfoundBio
- Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Renal cell carcinoma
Most Recent Events
- 21 May 2024 ProfoundBio has been acquired by Genmab
- 26 May 2023 NMPA approves clinical trials for PRO 1160 in China May 2023
- 15 Mar 2023 Phase-I/II clinical trials in Nasopharyngeal cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV)